Literature DB >> 14623124

Effect of JTC-801 (nociceptin antagonist) on neuropathic pain in a rat model.

Hidemichi Suyama1, Masashi Kawamoto, Syafruddin Gaus, Osafumi Yuge.   

Abstract

JTC-801, a nociceptin antagonist, may alleviate neuropathic pain because nociceptin has been shown to produce pain modulation. We report that JTC-801 alleviates heat-evoked hyperalgesia and investigated the possible protective effect on osteoporosis induced by chronic constriction injury (CCI) in rats. JTC-801 was given orally to rats with CCI at 0% (vehicle), 0.03% (low dose), or 0.06% (high dose) in food. Paw withdrawal latency (PWL) to heat, bone mineral content (BMC) and bone mineral density (BMD) of the whole tibial bone were measured. JTC-801 dose-dependently normalized PWL. Although JTC-801 did not inhibit a CCI-induced decrease in BMC and BMD, it inhibited an increase in the number of osteoclasts in the JTC-801 groups. JTC-801, given orally in food, alleviated heat-evoked hyperalgesia in CCI rats, suggesting that it is useful for the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623124     DOI: 10.1016/s0304-3940(03)00502-0

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

Review 1.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

2.  Activity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.

Authors:  Taline V Khroyan; Willma E Polgar; Juan Orduna; Faming Jiang; Cris Olsen; Lawrence Toll; Nurulain T Zaveri
Journal:  Eur J Pharmacol       Date:  2009-03-12       Impact factor: 4.432

3.  Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Authors:  Taline V Khroyan; Willma E Polgar; Faming Jiang; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2009-08-27       Impact factor: 4.030

4.  Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.

Authors:  Y Zhang; C D Simpson-Durand; K M Standifer
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

5.  Activities of mixed NOP and mu-opioid receptor ligands.

Authors:  B Spagnolo; G Calo; W E Polgar; F Jiang; C M Olsen; I Berzetei-Gurske; T V Khroyan; S M Husbands; J W Lewis; L Toll; N T Zaveri
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

Review 6.  The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.

Authors:  Lawrence Toll; Andrea Cippitelli; Akihiko Ozawa
Journal:  CNS Drugs       Date:  2021-05-31       Impact factor: 6.497

7.  Effect of peripheral neuropathy on bone mineral density in adults with diabetes: A systematic review of the literature and meta-analysis.

Authors:  Mahshid Mohseni; Pooya Hosseinzadeh; Roberto Civitelli; Seth Eisen
Journal:  Bone       Date:  2021-03-20       Impact factor: 4.626

8.  Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats.

Authors:  G Delaney; K L Dawe; R Hogan; T Hunjan; J Roper; G Hazell; S J Lolait; A J Fulford
Journal:  J Neuroendocrinol       Date:  2012-12       Impact factor: 3.627

9.  Increased nociceptive sensitivity and nociceptin/orphanin FQ levels in a rat model of PTSD.

Authors:  Yong Zhang; Priyam R Gandhi; Kelly M Standifer
Journal:  Mol Pain       Date:  2012-10-20       Impact factor: 3.395

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.